We advise you

together, physician and pharmacist, as partners.

We advise you as a partner

Prof. Dr. Peter Bramlage

Prof. Dr. Peter Bramlage, FESC, FACC

Partnership Dr. Bramlage & Dr. Hankowitz

Dr. Bramlage received his medical training at the Universities of Gießen, Vienna, and Columbia (Missouri, USA). Early on, he focused on experimental and clinical cardiology, achieving a PhD from the Max Planck Institute for Physiological and Clinical Research (Bad Nauheim). He also worked at the Medical Clinic and Outpatient Clinic for Cardiology and Angiology at the Charité University Hospital. This topic also shaped his postdoctoral work at the Institute for Clinical Pharmacology at TU Dresden. In addition, he has a number of years of industrial experience, working at Sanofi-Aventis in the field of cardiovascular disease.


Today, he is mainly associated with research in the areas of pharmaceuticals and medical devices after market launch. For this, he conducts the required registries and studies, either in the Institute itself, or as an external project in which he provides consultation, advising on the analysis, interpretation and publication of the data. This focus is demonstrated by the publication of over 250 articles in peer-reviewed journals, as shown below.


Publications listed on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/?term=Bramlage+P
List of publications on ResearchGate: https://www.researchgate.net/profile/Peter_Bramlage


Prof. Dr. med. Peter Bramlage
Tel.: +49 3379-314 78 90
email: peter.bramlage(at)ippmed.de

Dr. Johannes Hankowitz

Dr. Johannes Hankowitz

Partnership Dr. Bramlage & Dr. Hankowitz

Dr. Hankowitz studied pharmacy and philosophy with a focus on ethics, scientific theory, and structural research at the University of Münster and the Max Planck Institute for Biochemistry in Martinsried, near Munich, Germany. His doctoral dissertation, completed at the Institute for Clinical Chemistry, was on the topic of the effects of drugs on signal transduction in atherogenic processes. He subsequently worked as a research associate at the Regensburg University Hospital, in the Institute for Clinical Chemistry, focusing on immunology and oncology.

During his work, Dr Hankowitz received a Master’s degree in European Studies (M.E.S.) from the RWTH Aachen University, with a legal thesis on pharmacovigilance. He then moved to Sanofi Winthrop, working in the field of antithrombotics. He later became Medical Director of Sanofi-Synthelabo in the areas of thrombosis, cardiology, and the CNS, and Director of Medicine and Marketing for thrombosis and cardiology. Following this, he was the Head of Medicine and Pharmacy at Winthrop Arzneimittel GmbH, and was a company Director. Dr Hankowitz has experience in all aspects relevant to the AMG (German Medicinal Products Act), including data management, risk categorisation, and controlled drugs; being a Qualified Person; and marketing management.

Mr. Hankowitz is owner and editor of AMNOG-monitor – an interactive analysis tool for evaluation of all G-BA resolutions according to §35a SGB V. He is an expert of early benefit assessment in Germany including phase III clinical programme, Joint Scientific Advise (BfArM & G-BA), strategic consulting & compilation of benefit dossiers and price negotiations.


Dr. Johannes Hankowitz
Tel.: +49 89 18948312
email: johannes.hankowitz(at)ippmed.de